Filing Flows › Atrium Therapeutics (RNA) › Q2 2026
Atrium Therapeutics (RNA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Atrium Therapeutics (RNA) reported revenue of $3.0M for the second quarter 2026 (Q2 2026), -22% from a year earlier and -85% from the quarter before. Operating margin was -752.9%, net loss $20.2M (672.0% of revenue).
Atrium Therapeutics, Q2 2026: revenue $3.0M (-22% year over year), operating margin -752.9%, net loss $20.2M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.0M | -85% | -22% |
| Operating profit | −$22.6M | — | — |
| Net earnings | −$20.2M | — | — |
| Operating cash flow | −$3.9M | — | — |
What changed
Revenue was $3.0M in Q2 2026, down 22% year over year and down 85% from the previous quarter.
Operating costs exceeded revenue by $22.6M, an operating margin of -752.9%. Total costs grew 53% against a revenue fall of 22%. The fastest-growing cost line was General & admin (+201%). The quarter ended with a net loss of $20.2M, wider than the previous quarter's $16.6M loss.
Operating cash flow was −$3.9M. Non-cash charges added back $343K of depreciation and $893K of share-based compensation. Working capital and other items added $15.0M. Capital expenditures of $36K exceeded it, leaving free cash flow of −$4.0M.
Questions
What was Atrium Therapeutics' revenue in the second quarter 2026?
Atrium Therapeutics (RNA) reported revenue of $3.0M for the second quarter 2026 (Q2 2026), -22% from a year earlier and -85% from the quarter before.
Was Atrium Therapeutics profitable in the second quarter 2026?
Operating loss was $22.6M (-752.9% of revenue) and net loss $20.2M.